Company profile: Kailos Genetics
1.1 - Company Overview
Company description
- Provider of personalized health information and clinical genetic assays on a patented technology platform, offering Expedioâ„¢ Hereditary Cancer Risk Testing, Inspexionâ„¢ Pharmacogenetic Testing, Kailos Laboratory Services, Reagents and Sequencing Solutions, and Assure Sentinelâ„¢ COVID-19 Testing, leveraging next generation sequencing and CAP-accredited laboratory support.
Products and services
- Kailos Laboratory Services: CAP-accredited laboratory–backed service combines next generation sequencing with analytics to produce comprehensive genetic information
- Expedio™ Hereditary Cancer Risk Testing: Next generation DNA sequencing–based assay identifies hereditary cancer mutations and delivers comprehensive genetic variation information for integration into health information systems
- Inspexion™ Pharmacogenetic Testing: Next generation DNA sequencing test supplies detailed pharmacogenetics information for integration into health information systems
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kailos Genetics
AltheaDx
HQ: United States
Website
- Description: Provider of molecular diagnostics and PCR-based services, including molecular biomarker discovery, assay development and validation, prospective/retrospective clinical trial testing, and gene expression and genotyping analysis for pre-clinical and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltheaDx company profile →
DermTech
HQ: United States
Website
- Description: Provider of non-invasive qPCR assays for skin samples collected via adhesive tape biopsy, analyzing multiple gene targets' RNA expression. Offerings include the DermTech Melanoma Test, a genomic test using adhesive tape-collected skin cells to detect markers associated with melanoma with a 99% negative predictive value, anticipated to be provided through a CLIA-certified laboratory in San Diego.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DermTech company profile →
Vivet Therapeutics
HQ: France
Website
- Description: Provider of AAV-based gene therapies for orphan diseases, including VTX-801 for Wilson’s disease, VTX-802 for Progressive Familial Intrahepatic Cholestasis Type 2, VTX-803 for Progressive Familial Intrahepatic Cholestasis Type 3, VTX-804 for Citrullinemia Type 1, and VTX-806 for Cerebrotendinous Xanthomatosis, plus VTX-PSM, a non-integrative viral technology for sustainable transgene expression, partnered with FIMA/CIMA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivet Therapeutics company profile →
Mirvie
HQ: United States
Website
- Description: Provider of precise, actionable, non-invasive maternal-fetal health tests, including the Mirvie RNA Platform—a blood test that predicts pregnancy complications by analyzing RNA messages to assess risk independent of demographics and clinical factors—and clinical research and decentralized trials leveraging mobile-friendly virtual recruitment and community hospitals to validate and accelerate pregnancy complication research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirvie company profile →
Alios Biopharma
HQ: United States
Website
- Description: Provider of novel medicines for viral diseases, leveraging platform technologies including small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate-protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alios Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kailos Genetics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kailos Genetics
2.2 - Growth funds investing in similar companies to Kailos Genetics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kailos Genetics
4.2 - Public trading comparable groups for Kailos Genetics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →